Publicaciones en las que colabora con Rafael Franco Fernandez (46)

2023

  1. One-way or two-way sweet link between theobromine and depression?

    BMC Psychiatry

  2. The adenosine A2A receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling

    International Review of Neurobiology (Academic Press Inc.), pp. 49-71

  3. The olfactory Olfr-78/51E2 receptor interacts with the adenosine A2A receptor. Effect of menthol and 1,8-cineole on A2A receptor-mediated signaling

    Frontiers in Pharmacology, Vol. 14

2022

  1. Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPswe Alzheimer’s Disease Mouse Model

    International Journal of Molecular Sciences, Vol. 23, Núm. 7

  2. Plant-derived compounds, vitagens, vitagenes and mitochondrial function

    PharmaNutrition

2021

  1. Antixoxidant supplements versus health benefits of brief/intermittent exposure to potentially toxic physical or chemical agents

    Current Issues in Molecular Biology, Vol. 43, Núm. 2, pp. 650-664

  2. Cuprizone‐induced neurotoxicity in human neural cell lines is mediated by a reversible mitochondrial dysfunction: Relevance for demyelination models

    Brain Sciences, Vol. 11, Núm. 2, pp. 1-16

2020

  1. Adenosine a2a and a3 receptors are able to interact with each other. A further piece in the puzzle of adenosine receptor-mediated signaling

    International Journal of Molecular Sciences, Vol. 21, Núm. 14, pp. 1-14

  2. Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates

    Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164

  3. Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum

    Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42

  4. Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease

    Frontiers in Aging Neuroscience, Vol. 12

  5. Natural Compounds as Guides for the Discovery of Drugs Targeting G-Protein-Coupled Receptors

    Molecules (Basel, Switzerland), Vol. 25, Núm. 21

2019

  1. Antioxidant defense mechanisms in erythrocytes and in the central nervous system

    Antioxidants, Vol. 8, Núm. 2

  2. Antioxidants versus food antioxidant additives and food preservatives

    Antioxidants, Vol. 8, Núm. 11

  3. Hormetic and mitochondria-related mechanisms of antioxidant action of phytochemicals

    Antioxidants, Vol. 8, Núm. 9

  4. Lessons on differential neuronal-death-vulnerability from familial cases of parkinson’s and alzheimer’s diseases

    International Journal of Molecular Sciences, Vol. 20, Núm. 13

  5. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

  6. Why have transgenic rodent models failed to successfully mimic Alzheimer’s disease. How can we develop effective drugs without them?

    Expert Opinion on Drug Discovery

2018

  1. Biased receptor functionality versus biased agonism in G-protein-coupled receptors

    Biomolecular Concepts, Vol. 9, Núm. 1, pp. 143-154

  2. Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice

    Scientific Reports, Vol. 8, Núm. 1